Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: Subconjunctival Aflibercept Injection for Corneal Neovascularization
Brief Summary:
The cornea is the clear front part of the eye. Corneal neovascularization, the excessive growth of blood vessels into the cornea, is a sight-threatening condition. Corneal neovascularization is also a well recognized risk factor for corneal graft failure. The current standard of care to prevent graft rejection includes use of topical steroids and medicines that suppress the immune system. These medicines do not address corneal neovascularization. The purpose of the study is to establish the safety and potential efficacy of subconjunctival injections of aflibercept (EYLEA® , marketed by Regeneron) injection in inducing regression of blood vessels growing into the cornea and promoting graft survival.
This study is being conducted by Dr. Balamurali Ambati at the Moran Eye Center.